Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 16, Number 7—July 2010
Synopsis

Oseltamivir Resistance in Adult Oncology and Hematology Patients Infected with Pandemic (H1N1) 2009 Virus, Australia

Adrian R. TramontanaComments to Author , Biju George, Aeron C. Hurt, Joseph S. Doyle, Katherine Langan, Alistair B. Reid, Janet M. Harper, Karin Thursky, Leon J. Worth, Dominic E Dwyer, C. Orla Morrissey, Paul D.R. Johnson, Kirsty L. Buising, Simon James Harrison, John F. Seymour, Patricia E. Ferguson, Bin Wang, Justin T. Denholm, Allen C. Cheng, and Monica Slavin
Author affiliations: Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia (A.R. Tramontana, K. Thursky, L.J. Worth, S.J. Harrison, J.F. Seymour, M. Slavin); Western Hospital, Footscray, Victoria, Australia (A.R. Tramontana); Westmead Hospital, Sydney, New South Wales, Australia (B. George, D.E. Dwyer, B. Wang), World Health Organization Collaborating Centre for Reference and Research on Influenza, North Melbourne, Victoria, Australia (A.C. Hurt); The Alfred Hospital, Prahran, Victoria, Australia (J.S. Doyle, C.O. Morrissey); Austin Health, Heidelberg, Victoria, Australia (K. Langan, P.D.R. Johnson); St. Vincent’s Hospital, Melbourne, Victoria, Australia (A.B. Reid, K.L. Buising); Royal Melbourne Hospital, Melbourne (J.M. Harper, J.T. Denholm, M. Slavin); Centre for Infectious Diseases and Microbiology, Sydney (P.E. Ferguson); Monash University, Prahran (A.C. Cheng)

Main Article

Table 2

Characteristics of 4 patients infected with oseltamivir-resistant pandemic influenza A (H1N1) virus isolates, Australia*†

Characteristic Patient no.
1 5 12 20
Within 100 days of HSCT‡ No Yes No –
Time to development of resistance, d 22 11§ 8 4
Time of last positive NAT result, d 28 16 8 4
Change to zanamivir Yes No No No
Time to zanamivir, d 36 – – –
Died Yes Yes No No
LOS, d 39 66 21 9

*HSCT, hematopoietic stem cell transplant; NAT, nucleic acid test; LOS, length of stay.
†Oseltamivir resistance was influenza virus with H275Y mutation.
‡Time from commencement of oseltamivir.
§Detected in bronchoalveolar lavage specimen with negative NAT on nasopharyngeal swab 3 d before first and 10 d after last bronchoscopy. This patient received oseltamivir for 5 d.

Main Article

Page created: March 02, 2011
Page updated: March 02, 2011
Page reviewed: March 02, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external